DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for beta-thalassemia intermedia — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBeta-thalassemia intermedia maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedHydroxyureaApproved drug
Structures already discussed alongside beta-thalassemia intermedia in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Periplasmic portion of the Helicobacter pylori chemoreceptor TlpB — Hydroxyurea has a real, experimentally solved structure in complex with this target (PDB 3UB9, 1.42 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet nhydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3UB9 · 1.42 Å · ligand Hydroxyurea (NHY). Experimental structure, not a prediction.
What the evidence adds up to
Life expectancy in homozygous beta-thalassemia improved markedly over the past three decades due to adequate transfusion regimens and nightly subcutaneous desferrioxamine, with the first successful cure by bone marrow transplantation in 1981. For beta-thalassemia intermedia specifically, knowledge of clinical morbidities has increased but the optimal management plan remains hard to identify, with several controversies and no treatment guidelines for many complications. A 2024 study of 54 beta-thalassemia major patients undergoing haematopoietic stem cell transplantation with myeloablative conditioning reported overall survival of 70.4%. Disease-free survival was 63% with matched sibling donors and 57.7% with fully matched parents as donors; the difference was not statistically significant. Seven patients had graft rejection, and the most common cause of death was neutropenic sepsis followed by acute graft-versus-host disease.
In a 2019 laboratory study, simvastatin and romidepsin were tested in combination on erythroid cells. The combination produced a 3.09-fold increase in fetal haemoglobin production compared to the control group. Simvastatin inhibited BCL11a expression (0.065-fold) and romidepsin inhibited HDAC1 expression (0.47-fold). The authors proposed that combination therapy might ameliorate clinical manifestations in beta-thalassemia and sickle cell disease with at least side effects and reduce the need for blood transfusion, but no clinical trial data in patients were provided.
A 2025 study compared immune checkpoint expression in 140 beta-thalassemia patients on HbF-augmenting drugs (hydroxyurea and thalidomide), 33 patients on regular transfusions, and 27 healthy controls. LAG-3 expression was increased in all patients regardless of treatment. CTLA-4 was increased in patients on regular transfusions. TIM-3 and PD-1 were higher in patients taking HbF augmentation therapy compared to transfusion patients or controls. Correlation between serum ferritin and immune checkpoints was very weak to none. The authors attributed these alterations to thalassemia itself, repeated blood product exposure, recurrent infections, and immunomodulatory drugs.
What is still missing are randomised controlled trials comparing HbF-augmenting drugs (hydroxyurea, thalidomide, simvastatin, romidepsin) against each other or against placebo in beta-thalassemia intermedia specifically, with transfusion requirement as a primary endpoint. No trial has tested the simvastatin-romidepsin combination in humans. The immune checkpoint findings are descriptive and lack functional data linking expression changes to infection risk or treatment response. Funding for multicentre trials in thalassemia intermedia, which is less common than thalassemia major, remains limited.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Hematology · 1997 · 24 citations
Treatment of β-thalassemia
AbstractThe striking improvement in the life expectancy of patients with homozygous beta-thalassemia observed over the past three decades is mainly due to the institution of adequate transfusion regimens and effective iron chelation therapy with nightly subcutaneous desferrioxamine. The prognosis appears particularly favorable for children with thalassemia born since these methods have become widely available. The first successful "cure" of beta-thalassemia was achieved in 1981 after bone marrow transplantation. Recent advances in transfusion techniques, pharmacology, molecular genetics, transplant immunology, and clinical practice today offer considerable promise in further advancing our knowledge and treatment of this disease.
Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction.
AbstractOBJECTIVE: Hemoglobinopathies such as beta-thalassemia and sickle cell disease (SCD) are inherited disorders that are caused by mutations in beta-globin chain. Gamma-globin gene reactivation can ameliorate clinical manifestations of betathalassemia and SCD. Drugs that induce fetal hemoglobin (HbF) can be promising tools for treatment of beta-thalassemia and SCD patients. Recently, it has been shown that Simvastatin (SIM) and Romidepsin (ROM) induce HbF. SIM is a BCL11a inhibitor and ROM is a HDAC inhibitor and both of these drugs are Food and Drug Administration (FDA)-approved for hypercholesterolemia and cutaneous T-cell lymphoma respectively. Our aim was to evaluate the synergistic effects of these drugs in inducing HbF. MATERIALS AND METHODS: day of erythroid differentiation by real-time polymerase chain reaction (PCR) and immunocytochemistry. RESULTS: Our results showed that combination of SIM and ROM significantly increased Gamma-globin gene expression and inhibit BCL11a and HDAC expression compared to results of using each of them alone. SIM and ROM lead to 3.09- fold increase in HbF production compared to the control group. Also, SIM inhibited BCL11a expression (0.065-fold) and ROM inhibited HDAC1 expression (0.47-fold) as two important inhibitors of HbF production after birth. CONCLUSION: We propose combination therapy of these drugs may be ameliorate clinical manifestation in beta-thalassemia and SCD with at least side effects and reduce the need for blood transfusion.
Journal of Pediatric Hematology/Oncology · 2018 · 10 citations
Management of Children With β-Thalassemia Intermedia: Overview, Recent Advances, and Treatment Challenges
AbstractOur knowledge of the various clinical morbidities that thalassemia intermedia (TI) patients endure has substantially increased over the past decade. It is mandatory to grasp a solid understanding of disease-specific complications in order to tailor management. The optimal course of management for TI patients has been hard to identify, and several controversies remain with regard to the best treatment plan. Although advances in TI are moving at a fast pace, many complications remain with no treatment guidelines. Studies that expand our understanding of the mechanisms and risk factors, as well as clinical trials evaluating the roles of available treatments, will help establish management guidelines that improve patient care. Novel therapeutic modalities are now emerging. This article focuses on the management of children with β-TI. We present various clinical morbidities and their association with the underlying disease pathophysiology and risk factors. All therapeutic options, recent advances, and treatment challenges were reviewed.
Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study
AbstractINTRODUCTION: Thalassemia intermedia is a type of anemia which has several treatments modalities. We aimed to study the cost effectiveness of two treatments, including blood transfusion and hydroxyurea, in patients with beta-thalassemia intermedia in south of Iran referred to a referral center affiliated to Iran, Shiraz University of Medical Sciences in 2015. MATERIALS AND METHODS: This was a cost-effectiveness study which was conducted on 122 patients with beta-thalassemia intermedia. The indicator of effectiveness in this study was the reduction of growth disorder (normal BMI). Data analysis was done using SPSS 21, Excel 2010 and Treeage 2011. Finally, the one-way sensitivity analysis was performed to determine the robustness of the results. RESULTS: The average annual costs of blood transfusion and the use of hydroxyurea in 2015 were 20733.27 purchasing power parity (PPP)$ and 7040.29 PPP$, respectively. The effectiveness of blood transfusion was57.4% while in hydroxyurea group was 60.7%. CONCLUSION: The results showed that the cost effectiveness of using hydroxyurea was more than that of blood transfusion. Therefore, it is recommended that the use of hydroxyurea in the treatment of patients with beta-thalassemia intermedia would become the first priority, and more basic and supplementary insurance coverage for treating such patients using hydroxyurea should be considered.
Journal of College of Physicians And Surgeons Pakistan · 2024 · 2 citations · open access
Outcomes of Haematopoietic Stem Cell Transplantation in Beta Thalassemia Major with Fully Matched Parents as Donor
AbstractOBJECTIVE: To determine the outcome of beta thalassemia major (BTM) patients undergoing haematopoietic stem cells (HSCT), with fully matched parents as donors vs. matched sibling donors (MSD). STUDY DESIGN: Observational Study. Place and Duration of the Study: Department of Clinical Haematology and Bone Marrow Transplantation Centre, Rawalpindi, Pakistan, from January 2013 to July 2023. METHODOLOGY: Group A consisted of BTM patients who underwent HSCT with fully matched siblings as donors, and Group B consisted of BTM patients who underwent HSCT with fully matched parents as donors. Study data included the age and gender of both recipients and donors, source and dose of stem cells infused, and stage and grades of acute and chronic graft versus host disease (GvHD). All patients received Myeloablative conditioning regimen (MAC). Data were collected to assess patients' demographics, response to HSCT, remission rate, disease free survival (DFS), relapse, and GvHD free survival (GRFS), and overall survival (OS). RESULTS: The mean age of the 54 patients was 5.90 ± 3.29 years. The mean TNC and CD34 doses were 4.99 + 1.13 and 5.42 + 3.70, respectively. Mean time for neutrophil engraftment in both groups was 14.88 + 4.51 days and platelets engraftment was 23.0 + 5.35 days. Most common cause of death was neutropenic sepsis followed by aGVHD. Seven patients had graft rejection. There was no significant association found between graft rejection with donor relation though graft rejection was higher in OS in this study was 70.4%. OS was equal in both groups. Disease free survival was superior in MSD (63%) than parent group (57.7%). CONCLUSION: Allogenic bone marrow transplantation with parents as donors in BTM patients yields outcomes comparable to those with matched sibling donors. This finding is especially relevant in regions like Pakistan, where donor registries and high-resolution HLA typing may be limited. KEY WORDS: Beta thalassemia major, Haematopoietic stem cell transplant, Post-transplant outcome.
Turkish Journal of Hematology · 2025 · 1 citations · open access
Expression of Immune Checkpoints LAG-3, CTLA-4, TIM-3 and PD-1 in Beta Thalassemia patients Treated using HbF Augmentation Therapy and Regular Transfusions
AbstractIntroduction: Beta-thalassemia is an inherited hemoglobin disorder caused by mutations in HBB gene encoding beta globin chains.Severe anemia secondary to defective globin chains, chronic hemolysis and ineffective erythropoiesis requires transfusion support from early childhood.Recently used treatment options with promising results in resource limited countries includes drugs which augment HbF such as hydroxyurea and thalidomide.Although effective in alleviating anemia and related symptoms, these drugs particularly thalidomide has been known for its immunomodulatory role.Similarly, repeated transfusions with compromised immune system increases the risk of infections and weakened immunity.One of the key regulators of immune systems includes immune checkpoints, cell surface molecules on immune cells.Limited studies are available on immune checkpoints such as LAG-3, CTLA-4, TIM-3 and PD-1 expression in thalassemia and its treatment.Objectives: This study aimed to compare LAG-3, CTLA-4, TIM-3, and PD-1 expression in patients treated using HbF augmenting drugs or transfusions and with iron overload.These findings will provide an insight into the immune regulation in betathalassemia in response to treatment.Methods: In this study, the expression of LAG-3, CTLA-4, TIM-3 and PD-1 was quantified using real time PCR in patients managed on blood transfusions (n=33) or HbF augmenting drugs (n=140) and compared with healthy controls (n=27).Results: Our results show an increased expression of LAG-3 in patients regardless of treatment whereas increased CTLA-4 in patients on regular transfusions.On the other hand, the expressions of TIM-3 and PD-1 were higher in patients taking HbF augmentation therapy compared to patients on blood transfusions or the healthy controls.A very weak to no correlation was found between serum ferritin and immune checkpoints.Conclusions: These findings are suggestive of alterations in immune regulation in betathalassemia which could be attributed to thalassemia itself, repeated exposure to blood products, recurrent infections and the immunomodulatory drugs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
